Skip to main content

Table 1 Patient characteristics of MDA groups and of total study population

From: Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis

  Early MDA (n = 94) Late MDA (n = 77) Never MDA (n = 97)
Age 50.1 ± 14 50.4 ± 13 52.8 ± 14
Male 57 (61) 41 (53) 44 (45)
Symptom duration in years 0.9 (0.2–2.4) 0.8 (0.3–1.5) 1.6 (0.4–4.1)
Disease activity at baseline
 Swollen joint count (66) 1 (1–3) 3 (1–4) 2 (0–6)$
 Tender joint count (68) 1 (0–3) 3 (2–7)* 5 (3–12)$
 LEI 0 (0–0) 0 (0–1)* 1 (0–2)$
 HAQ 0.13 (0.00–0.63) 0.63 (0.38–0.89)* 0.88 (0.63–1.38)$
 PASI 1.5 (0.4–3.8) 2.3 (0.3–4.1) 3 (1.2–6.1)$
 VAS global 21 (9–37) 46 (24–66)* 55 (40–70)$
 VAS pain 17 (9–44) 47 (30–63)* 56 (44–74)$
Medication in first year
 Any DMARD 62 (66) 63 (82)* 85 (88)$
 Methotrexate 57 (61) 61 (79)* 79 (81)$
 Sulfasalazine 8 (9) 14 (18) 23 (24)$
 Hydroxychloroquine 4 (4) 11 (14) 8 (8)
 Leflunomide 8 (9) 8 (10) 17 (18)
 Prednisone (oral) 13 (14) 14 (18) 18 (19)
 Prednisone (intramuscular injection) 11 (12) 21 (27)* 34 (35)$
 Prednisone (intra-articular injection) 29 (31) 27 (35) 15 (15)$
 Biological 5 (5) 12 (16)* 16 (16)
  1. Results shown as mean ± standard deviation, n (%) or median (interquartile range). *Early vs. Late MDA and $MDA vs. Never MDA p < 0.05 of t-test (continuous data) or chi-squared (categorical data). MDA minimal disease activity, Early MDA MDA within 3 months, Late MDA MDA between 3 and 12, Never MDA no MDA within first year. LEI Leeds Enthesitis Index, HAQ Health Assessment Questionnaire, PASI Psoriasis Area and Severity Index, VAS visual analogue scale, DMARD disease-modifying antirheumatic drug